XML 62 R50.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Royalty and Commercial Payment Purchase Agreements - Aronora (Details) |  | 1 Months Ended | 3 Months Ended |
--- | --- | --- | --- | ---
Apr. 07, 2019 USD ($) item | Sep. 30, 2019 USD ($) | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($)
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  | $ 15,000,000 | $ 9,600,000 |
Contingent consideration under RPAs, AAAs and CPPAs |  |  | 3,000,000 |  | $ 7,000,000
Short-term royalty and commercial payment receivables |  |  | 9,819,000 |  | 14,215,000
Aronora | Royalty Purchase Agreement |  |  |  |  |
Agreements |  |  |  |  |
Number of drug candidates | item | 5 |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |
Future non-royalty payments to be received (as a percent) | 5.00% |  |  |  |
Multiplier for cumulative amount of consideration paid | 2 |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | $ 6,000,000.0 | $ 3,000,000.0 |  |  |
Threshold amount of cumulative royalties on net sales per product | 250,000,000.0 |  |  |  |
Maximum royalty milestone payments to be paid per product | 85,000,000.0 |  |  |  |
Acquisition of royalty and commercial payment receivables, Long-Term | 9,000,000.0 |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs | 3,000,000.0 |  |  |  |
Amount of allowance for credit losses |  |  | $ 0 |  | $ 0
Aronora | Royalty Purchase Agreement | Minimum |  |  |  |  |
Agreements |  |  |  |  |
Threshold amount of cumulative royalties on net sales per product | 25,000,000.0 |  |  |  |
Aronora | Royalty Purchase Agreement | SVB Loan |  |  |  |  |
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | $ 3,000,000.0 |  |  |  |
Aronora | Royalty Purchase Agreement | Bayer Products |  |  |  |  |
Agreements |  |  |  |  |
Number of drug candidates | item | 3 |  |  |  |
Number of drug candidates subject to exclusive license option | item | 1 |  |  |  |
Royalties entity has right to receive (as a percent) | 100.00% |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |
Contingent future cash payment for each product | $ 1,000,000.0 |  |  |  |
Aronora | Royalty Purchase Agreement | Bayer Products | Maximum |  |  |  |  |
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs | $ 3,000,000.0 |  |  |  |
Aronora | Royalty Purchase Agreement | Non-Bayer Products |  |  |  |  |
Agreements |  |  |  |  |
Number of drug candidates | 2 |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of drug candidates subject to exclusive license option. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of drug candidates under the terms of the agreement. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Multiplier used in determining change in payment percentage. + References No definition available. + Details
Name: | xoma_AgreementPaymentPercentageFactor
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contingent future cash payment for each product. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_ContingentFutureCashPaymentsPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Threshold amount of cumulative royalties on net sales per product under the terms of the agreement + References No definition available. + Details
Name: | xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum amount of aggregate tiered royalty milestone payments to be made under the terms of the agreement. + References No definition available. + Details
Name: | xoma_MilestonesPaymentsToAggregateAmountOfPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchased percentage of non-royalties on net sales of products. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_RightsReceivableCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalties entity has the right to receive as a percentage of net sales. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AronoraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_BayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_NonBayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |